Corvus Pharmaceuticals (CRVS) Capital Expenditures (2015 - 2026)
Corvus Pharmaceuticals (CRVS) posted quarterly Capital Expenditures of $91000.0 for Q1 2026, up 152.78% year-over-year from $36000.0 in Q1 2025, and up 118.69% quarter-over-quarter from -$487000.0 in Q4 2025.
Powered by 
Analysis
Corvus Pharmaceuticals (CRVS) Capital Expenditures (2015 - 2026) Analysis & Trends
Corvus Pharmaceuticals' Capital Expenditures history runs 12 years deep, the most recent figure standing at $91000.0 for Q1 2026.
- In Q1 2026, Capital Expenditures rose 152.78% year-over-year to $91000.0; the TTM figure through Mar 2026 stood at -$283000.0 (down 181.32% YoY), while the FY2025 annual figure was -$338000.0, down 1307.14% from the prior year.
- Capital Expenditures for Q1 2026 stood at $91000.0, up from -$487000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $893000.0 in Q4 2024, with the low at -$487000.0 in Q4 2025.
- The 5-year median for Capital Expenditures is $21000.0 (2022), against an average of $6666.7.
- The sharpest annual moves came in 2024 and 2025: Capital Expenditures slumped 935.29% in 2024, then surged 206.8% in 2025.
- Corvus Pharmaceuticals' Capital Expenditures stood at $257000.0 in 2022, then slumped by 86.77% to $34000.0 in 2023, then surged by 2526.47% to $893000.0 in 2024, then plunged by 154.54% to -$487000.0 in 2025, then surged by 118.69% to $91000.0 in 2026.
- Business Quant data shows CRVS's Capital Expenditures at $91000.0 in Q1 2026, -$487000.0 in Q4 2025, and $314000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 37.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 2.29 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.02 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 34.68 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 251.02 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Corvus Pharmaceuticals | 1.33 Bn | 1.12 Bn | - | 582,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 582,000.00 |
| Mar 31, 2026 | 91,000.00 |
| Dec 31, 2025 | -88,000.00 |
| Sep 30, 2025 | -85,000.00 |
| Jun 30, 2025 | -83,000.00 |
| Mar 31, 2025 | -82,000.00 |
| Dec 31, 2024 | 893,000.00 |
| Sep 30, 2024 | -294,000.00 |
| Jun 30, 2024 | -287,000.00 |
| Mar 31, 2024 | -284,000.00 |
| Dec 31, 2023 | -1.10 Mn |
| Mar 31, 2023 | 34,000.00 |
| Dec 31, 2022 | -1.24 Mn |
| Sep 30, 2022 | 265,000.00 |
| Dec 31, 2021 | -43,000.00 |
| Sep 30, 2021 | -37,000.00 |
| Jun 30, 2021 | -762,000.00 |
| Mar 31, 2021 | 664,000.00 |
| Dec 31, 2020 | -175,000.00 |
| Sep 30, 2020 | 88,000.00 |